OKYO Pharma stock rises after FDA confirms Phase 2b/3 trial design

Published 2 hours ago

Source: investing.com

OKYO Pharma stock rises after FDA confirms Phase 2b/3 trial design

This article has no content available.

Read Original Article

Related Articles from investing.com

Wall Street largely flat as focus turns to Big Tech after Fed holds rates steady

Needham lowers Extreme Networks stock price target on margin outlook

Progressive stock price target lowered to $232 by BMO Capital

Form 144 Strategy Inc For: 28 January

Check Point stock price target lowered to $200 from $220 at Cantor Fitzgerald

US ICE releases man in Minnesota as agency head faced contempt